← Evidence map

ArticleEuropean urology open science2026

Mapping of QLQ-C30 and QLQ-PR25 Scores to EQ-5D-5L Utility Values for Patients with Prostate Cancer Receiving Novel Androgen Receptor Signaling Inhibitors.

Shao-Yuan Hao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

1 paper cites it

2026

this papercites it

Mapping of QLQ-C30 and QLQ-PR25 Scores to EQ-5D-5L Utility Values for Patients with Prostate Cancer Receiving Novel Androgen Receptor Signaling Inhibitors. | Socratic